Mind Medicine MindMed Inc. (MMED.CN)

The psychedelic space is coming to the forefront for investors who ses this as Cannabis 3.0, but these are not recreational products. Rather, the breakthroughs are coming in medicine to treat PTSD, addictions and anxiety, areas showing promise through psychs. Such companies are building a pharmaceutical platform (drugs to sell to patients). Big pharma isn't in this space yet, but will change over time. He prefers other companies to MMED in this space, but he isn't holding much in this sector yet.

This whole area is really quite interesting. The cannabis market was known to be a recreational market but this does not have the same mainstream acceptance as Cannabis. They will be doing research (clinical studies) to come out with new pharmaceuticals to treat mental illness and addiction. It will take multiple years to see the actual drug get to development. If you wanted to have a small piece in your portfolio, you would treat these as lottery tickets.

This is the next Cannabis area. It is the psychedelic area. Compounds can be pulled out and used for medical purposes. They want to design trials to use different compounds of mushroom to help with things like substance abuse.